Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage : A systematic review and meta-analysis
© 2021 John Wiley & Sons Ltd..
WHAT IS KNOWN AND OBJECTIVE: The benefits and risks of restarting antiplatelet therapy (APT) for patients with spontaneous intracranial haemorrhage (ICH) remain controversial. This meta-analysis was performed to explore the efficacy and safety of restarting APT for these patients.
METHODS: We followed the recommended PRISMA guidelines for systematic reviews. Studies from PubMed, Embase, Web of Science, CNKI and the Cochrane Library were systematically retrieved from the inception of each database to 31 July 2020. We also manually retrieved studies of reference.
RESULTS AND DISCUSSION: In this study, seven cohort studies and one randomized controlled trial (RCT) with subjects were included. APT resumption after spontaneous ICH did not significantly increase the risk of major haemorrhagic events (HR 1.15; 95% CI: 0.70-1.89; p = .59). However, it did not significantly reduce the risk of a composite endpoint concerning occlusive/thromboembolic events (HR 0.98; 95% CI: 0.81-1.19; p = .83) and all-cause mortality (HR 0.93; 95% CI: 0.80-1.08; p = .35).
WHAT IS NEW AND CONCLUSION: Restarting APT for patients with spontaneous ICH is generally safe. However, the benefits of reducing the risk of ischaemic vascular events and all-cause mortality were not apparent. More RCTs are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Journal of clinical pharmacy and therapeutics - 46(2021), 4 vom: 30. Aug., Seite 957-965 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Bo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jcpt.13377 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320987337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320987337 | ||
| 003 | DE-627 | ||
| 005 | 20231225174839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jcpt.13377 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320987337 | ||
| 035 | |a (NLM)33537999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Bo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage |b A systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 John Wiley & Sons Ltd. | ||
| 520 | |a WHAT IS KNOWN AND OBJECTIVE: The benefits and risks of restarting antiplatelet therapy (APT) for patients with spontaneous intracranial haemorrhage (ICH) remain controversial. This meta-analysis was performed to explore the efficacy and safety of restarting APT for these patients | ||
| 520 | |a METHODS: We followed the recommended PRISMA guidelines for systematic reviews. Studies from PubMed, Embase, Web of Science, CNKI and the Cochrane Library were systematically retrieved from the inception of each database to 31 July 2020. We also manually retrieved studies of reference | ||
| 520 | |a RESULTS AND DISCUSSION: In this study, seven cohort studies and one randomized controlled trial (RCT) with subjects were included. APT resumption after spontaneous ICH did not significantly increase the risk of major haemorrhagic events (HR 1.15; 95% CI: 0.70-1.89; p = .59). However, it did not significantly reduce the risk of a composite endpoint concerning occlusive/thromboembolic events (HR 0.98; 95% CI: 0.81-1.19; p = .83) and all-cause mortality (HR 0.93; 95% CI: 0.80-1.08; p = .35) | ||
| 520 | |a WHAT IS NEW AND CONCLUSION: Restarting APT for patients with spontaneous ICH is generally safe. However, the benefits of reducing the risk of ischaemic vascular events and all-cause mortality were not apparent. More RCTs are required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a antiplatelet therapy | |
| 650 | 4 | |a antithrombotic therapy | |
| 650 | 4 | |a intracerebral haemorrhage | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a platelet aggregation inhibitor | |
| 650 | 4 | |a spontaneous intracranial haemorrhage | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Li, Jinze |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yirong |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a He, Shijia |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shushan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pharmacy and therapeutics |d 1995 |g 46(2021), 4 vom: 30. Aug., Seite 957-965 |w (DE-627)NLM012677221 |x 1365-2710 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:4 |g day:30 |g month:08 |g pages:957-965 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jcpt.13377 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 4 |b 30 |c 08 |h 957-965 | ||